![](https://investorshub.advfn.com/uicon/529502.png?cb=1651683647)
Sunday, November 20, 2022 1:33:13 PM
Recently, investigators at Weill Cornell Medicine researchers have received a five-year $5.7 million grant from the National Cancer Institute (NCI) at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups. Weill Cornell Medicine represents one of two founding members of the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)—part of a collaborative research network funded by the NCI to discover agents that prevent or intercept cancer in high-risk populations.
FACTS are stubborn things
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM